0000891293-19-000010.txt : 20190221
0000891293-19-000010.hdr.sgml : 20190221
20190221184602
ACCESSION NUMBER: 0000891293-19-000010
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190219
FILED AS OF DATE: 20190221
DATE AS OF CHANGE: 20190221
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KIRSKE DAVID
CENTRAL INDEX KEY: 0001276750
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-28386
FILM NUMBER: 19623500
MAIL ADDRESS:
STREET 1: C/O CTI BIOPHARMA CORP.
STREET 2: 3101 WESTERN AVE., SUITE 600
CITY: SEATTLE
STATE: WA
ZIP: 98121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CTI BIOPHARMA CORP
CENTRAL INDEX KEY: 0000891293
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 911533912
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
BUSINESS PHONE: 2062827100
MAIL ADDRESS:
STREET 1: 3101 WESTERN AVENUE
STREET 2: SUITE 800
CITY: SEATTLE
STATE: WA
ZIP: 98121
FORMER COMPANY:
FORMER CONFORMED NAME: CELL THERAPEUTICS INC
DATE OF NAME CHANGE: 19960321
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2019-02-19
0
0000891293
CTI BIOPHARMA CORP
ctic
0001276750
KIRSKE DAVID
C/O CTI BIOPHARMA CORP.
3101 WESTERN AVE., SUITE 800
SEATTLE
WA
98121
0
1
0
0
EVP, Chief Financial Officer
Non-Qualified Stock Option (right to buy)
0.9489
2019-02-19
4
A
0
500000
0
A
2029-02-19
Common Stock
500000
500000
D
1/3 of the shares subject to the Option shall vest on the one year anniversary of February 19, 2019, and 1/3 of the shares shall vest annually thereafter on February 19, subject to Reporting Person continuing to be an employee or service provider on each date, such that the Option shall be fully vested on February 19, 2022.
David H. Kirske
2019-02-19